Capricor FDA AdCom Deramiocel Rejection
Analysis based on 7 articles · First reported Aug 20, 2026 · Last updated Sep 02, 2026
The FDA's negative review and advisory committee vote caused a dramatic decline in Capricor's stock price, erasing significant market value and triggering securities fraud litigation. Investor confidence in the company's lead product candidate has been severely damaged, and the regulatory path for deramiocel is now highly uncertain.
Paragon Therapeutics faced a major regulatory setback when the FDA released briefing documents on July 27, 2026, questioning the statistical analysis of its cell therapy deramiocel for Duchenne muscular dystrophy-associated cardiomyopathy. The FDA stated that the benefit-risk assessment appeared unfavorable without evidence of effectiveness. On July 29, 2026, an FDA advisory committee voted 9-3 that the available evidence did not support the efficacy of deramiocel. Following these events, Capricor's stock plummeted, falling 62% on July 27 and another 36% on July 30 to close at $4.19. Subsequently, multiple law firms, including Glancy Prongay & Murray and the The Law Offices of Frank R. Cruz, filed or announced securities fraud class action lawsuits against Capricor, alleging the company made misleading statements about its clinical data and regulatory prospects. The class period is from December 17, 2025 to July 26, 2026, with a lead plaintiff deadline of September 28, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard